Skip to content
Screener

R&D at other companies

NeoGenomics logo
NeoGenomicsNEO
$10.76M+19.3%
Illumina logo
IlluminaILMN
$252M+2.0%
Veracyte logo
VeracyteVCYT
$27.1M+52.9%
Biodesix, Inc. logo
Biodesix, Inc.BDSX
$3.14M-4.1%
Guardant Health logo
Guardant HealthGH
$91.04M+2.8%
Natera, Inc. logo
Natera, Inc.NTRA
$228.07M+55.8%

Other financials

Income statement

See full
Revenue$15.5M-24.9%
Gross profit$281.0K-96.1%
Operating income-$32.2M-81.7%
Net income-$30.0M-90.7%
EPS (diluted)-$0.29-61.1%

Balance sheet

See full
Cash & equivalents$73.6M+3.7%
Total debt$39.0M-6.2%
Total equity$254.8M+22.9%
Total assets$325.4M+19.1%

Cash flow

See full
Operating cash flow-$22.5M-25.1%
CapEx$3.2M+27.1%
Free cash flow-$25.7M-25.4%

Valuation

See full
Market cap$1.51B+279%
Enterprise value$1.48B+283%
P/S23.4×+18.5×

Profitability

See full
Gross margin13.7%-19.6pp
Operating margin-158.9%-5,457pp
Net margin-148.1%+154pp
FCF margin-131.2%-453pp

Returns & leverage

See full
Return on equity-41.4%-6.7pp
Debt / equity0.2×0.0×
Current ratio6.6×-0.3×

Where this comes from

Reported directly by Personalis, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Personalis, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211896
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue (1)$15,472$20,605
Costs and expenses
Cost of revenue15,19113,398
Research and development14,53912,640
Selling, general and administrative (2)17,90312,263
Total costs and expenses47,63338,301
Loss from operations(32,161)(17,696)
Interest income2,1722,027

Item 1. Financial Statements

FAQ

What is Personalis, Inc.'s R&D?
Personalis, Inc. (PSNL) reported R&D of $14.54M in Q1 2026.
How has Personalis, Inc.'s R&D changed year-over-year?
Personalis, Inc.'s R&D increased by 15.0% year-over-year, from $12.64M to $14.54M.
What is the long-term trend for Personalis, Inc.'s R&D?
Over 4 years (2021 to 2025), Personalis, Inc.'s R&D has grown at a 0.5% compound annual growth rate (CAGR), from $49.31M to $50.26M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Personalis, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude